Breast Cancer

The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
Genomic profiles measured through circulating free DNA in the blood of patients with breast cancer may provide a more effective way to treat the disease and track its progression.
[[thumbnail_alt_text]]
Researchers examine how stem cells promote neuronal growth in tissue regeneration and in cancer progression.
[[thumbnail_alt_text]]
The researchers plan to present updated data at the European Society for Medical Oncology Breast Cancer conference in May.
[[thumbnail_alt_text]]
New information from the IQVIA “Global Medicine Spending and Usage Trends” report highlights the expected growth of specialty pharmacy spending by 2024.
[[thumbnail_alt_text]]
DCIS is a noninvasive condition in which abnormal cells are found in the lining of a breast duct but have not spread to other tissues in the breast.
[[thumbnail_alt_text]]
New research has examined the details surrounding the signaling molecule interleukin-2, which could lead to more targeted therapies for diseases such as cancer.
[[thumbnail_alt_text]]
Guidelines recommend that Ashkenazi Jewish women discuss genetic testing with physicians, but other women with breast cancer are less likely to receive a recommendation of testing.
[[thumbnail_alt_text]]
Research may lead to the development of new types of binding proteins for biological sugar structures, which play a significant role in cancer and infectious diseases.
[[thumbnail_alt_text]]
Patients with a history of cancer have a greater likelihood of developing atrial fibrillation, the most common heart rhythm disorder, compared with the general population.
[[thumbnail_alt_text]]
The new study has found that the lymphedema monitoring technology, marketed by LymphaTech, can effectively detect early arm swelling associated with lymphedema in breast cancer patients.
[[thumbnail_alt_text]]
Trastuzumab-dttb was first approved in January 2019 across all eligible indications, mainly adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer.
 
[[thumbnail_alt_text]]
The growth of the pipeline has led to increases in insurance carriers’ specialty plan spend.